Company · founded 2009
Viewpoint Molecular Targeting (United States)
Coralville, United States · viewpointmt.com
- Citations, last 5 years
- 114
- Works, last 5 years
- 15
- h-index
- 25
- Scientists listed
- 1
- Grants since 2016
- 15
Grants received
2024–2025 · research · R42
Antibody-based prertargeted alpha particle therapy for ovarian cancer
Jacob Houghton · Viewpoint Molecular Targeting (United States) · funded by National Institutes of Health
2022–2024 · research · R44
Image-guided dosimetry-based alpha particle therapy for neuroblastoma.
Alan Brent Packard · Viewpoint Molecular Targeting (United States) · funded by National Institutes of Health
2022–2025 · research · R44
Image-guided dosimetry-based alpha particle therapy for neuroblastoma.
Alan Brent Packard · Viewpoint Molecular Targeting (United States) · funded by National Institutes of Health
2020–2022 · research · R44
Preclinical pharmacology, toxicology, biodistribution and dosimetry, and radionuclide production CMC validation for Pb-212 receptor targeted alpha-particle therapy for neuroendocrine tumors.
Michael King Schultz · Viewpoint Molecular Targeting (United States) · funded by National Institutes of Health
2020–2022 · research · R44
GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for Pb-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma.
Michael King Schultz · Viewpoint Molecular Targeting (United States) · funded by National Institutes of Health
2020–2022 · research · R44
Preclinical pharmacology, toxicology, biodistribution and dosimetry, and radionuclide production CMC validation for Pb-212 receptor targeted alpha-particle therapy for neuroendocrine tumors.
Michael King Schultz · Viewpoint Molecular Targeting (United States) · funded by National Institutes of Health
2020–2022 · research · R44
GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for Pb-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma.
Michael King Schultz · Viewpoint Molecular Targeting (United States) · funded by National Institutes of Health
2019–2024 · research · R44
Combining receptor-targeted alpha particle therapy and immunotherapy to achieve complete responses in metastatic melanoma
Michael King Schultz · Viewpoint Molecular Targeting (United States) · funded by National Institutes of Health
2019 · research · R43
Receptor-targeted radionuclide therapy combined with immunotherapies to improve metastatic melanoma tumor response.
Frances L Johnson · Viewpoint Molecular Targeting (United States) · funded by National Institutes of Health
2019–2025 · research · R44
Combining receptor-targeted alpha particle therapy and immunotherapy to achieve complete responses in metastatic melanoma
Michael King Schultz · Viewpoint Molecular Targeting (United States) · funded by National Institutes of Health
2017 · research · R43
Production of Image-Guided Metastatic Melanoma Therapy Radiopharmaceuticals
Frances L Johnson · Viewpoint Molecular Targeting (United States) · funded by National Institutes of Health
2017–2019 · contract · N44
"Systemic Targeted Radionuclide Therapy for Metastatic Melanoma"Period of Performance: 9/18/2017 - 9/17/2019
Frances Johnson · Viewpoint Molecular Targeting (United States) · funded by National Institutes of Health
2017–2022 · research · R44
Phase 1 cross over biodistribution study of [203Pb]VMT01 for single photon emission computed tomography (SPECT) and [68Ga]VMT02 for positron emission tomography (PET) imaging of stage 4 melanoma
Frances L Johnson · Viewpoint Molecular Targeting (United States) · funded by National Institutes of Health
2017–2021 · research · R44
Phase 1 cross over biodistribution study of [203Pb]VMT01 for single photon emission computed tomography (SPECT) and [68Ga]VMT02 for positron emission tomography (PET) imaging of stage 4 melanoma
Frances L Johnson · Viewpoint Molecular Targeting (United States) · funded by National Institutes of Health
2016–2017 · research · R43
Production of Image-Guided Metastatic Melanoma Therapy Radiopharmaceuticals
Frances L Johnson · Viewpoint Molecular Targeting (United States) · funded by National Institutes of Health
